重大事件即時報告 8-K 2026-07-21

Rein Therapeutics股東會通過增發股份及高層薪酬等四項提案

AI 繁中摘要

Rein Therapeutics（股票代碼：RNTX）於2026年7月20日舉行年度股東大會，並已向SEC提交8-K表格報告投票結果。所有四項提案均獲股東通過 📊

**主要投票結果如下：**

1. **選舉兩名第三類董事**— Josef H. von Rickenbach 與 Reinhard J. Ambros 博士均獲選，任期至2029年股東年會。  
   - von Rickenbach：贊成25,402,442票；反對13,202,963票；經紀人非投票25,098,629票  
   - Ambros：贊成25,404,238票；反對13,201,167票；經紀人非投票25,098,629票  

2. **批准修訂公司章程，將授權普通股從1億股增至2億股**— 結果：贊成61,004,221票；反對2,394,208票；棄權305,605票（無經紀人非投票）  
   此舉為公司未來融資、股權激勵或併購預留空間，惟可能對現有股東造成攤薄影響。

3. **批准聘任CBIZ CPAs P.C.為截至2026年12月31日財年的獨立註冊會計師事務所**— 贊成62,953,351票；反對172,420票；棄權578,263票（無經紀人非投票）

4. **諮詢性投票通過高層薪酬方案**— 贊成37,628,483票；反對914,331票；棄權62,591票；經紀人非投票25,098,629票  
   顯示股東對現有薪酬架構的廣泛支持。

所有議案均順利通過，反映股東對董事會及管理層方向的基本認同。授權股份增加為公司提供更大財務靈活性，而會計師事務所及薪酬方案獲批亦有助維持公司治理穩定性。

展開英文正文

8-K

 NASDAQ false 0001420565 0001420565 2026-07-20 2026-07-20 
  
  
 UNITED STATES
 SECURITIES AND EXCHANGE COMMISSION
 WASHINGTON, DC 20549
  
  

 FORM 8-K
  
  

 CURRENT REPORT
 Pursuant to Section 13 or 15(d)
 of the Securities Exchange Act of 1934
 Date of report (Date of earliest event reported): July 20, 2026
  
  

 REIN THERAPEUTICS, INC. 
 (Exact Name of Registrant as Specified in Its Charter)
  
  

  

Delaware
 
001-38130
 
13-4196017

(State or Other Jurisdiction
of Incorporation)
 
 (Commission
 File Number)

 
(I.R.S. Employer
Identification Number)
  

12407 N. Mopac Expy., Suite 250, #390

Austin, Texas 78758

(Address of principal executive offices)
 (737) 802-1989
 (Registrant’s telephone number, including area code)
 N/A
 (Former name or former address, if changed since last report)
  
  

 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions.
  

☐
 Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

  

☐
 Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14d-2(b)

  

☐
 Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)

  

☐
 Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)

 Securities registered pursuant to Section 12(b) of the Act:
  

 Title of each class

 
 Trading
Symbol(s)

 
 Name of each exchange
on which registered

Common stock: Par value $.001
 
RNTX
 
 Nasdaq Capital Market 
 Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
  

 
Emerging growth company ☐
 If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
  
  
  

 

 Item 5.07 Submission of Matters to a Vote of Security Holders 
 On July 20, 2026, Rein Therapeutics, Inc. held its 2026 Annual Meeting of Stockholders, for the purposes of: 
  

 
•
 
 Electing two Class III directors to serve on our Board of Directors until our 2029 annual meeting of stockholders and until their respective successors are duly elected and qualified; 

  

 
•
 
 Approving an amendment to our restated certificate of incorporation to increase the number of authorized shares of common stock from 100 million shares to 200 million shares; 

  

 
•
 
 Ratifying the appointment of CBIZ CPAs P.C. as our independent registered public accounting firm for the year ending December 31, 2026; and 

  

 
•
 
 Approving, on an advisory basis, the compensation of our named executive officers disclosed in the Proxy Statement. 

 Our stockholders elected two Class III directors, namely Josef H. von Rickenbach and Reinhard J. Ambros, Ph.D., with shares voted as follows: 
  

 Name

 
 For

 
 Withheld

 
 Broker
 Non-Votes

 Josef H. von Rickenbach

 
25,402,442
 
13,202,963
 
25,098,629

 Reinhard J. Ambros, Ph.D

 
25,404,238
 
13,201,167
 
25,098,629

 In addition, our stockholders approved an amendment to our restated certificate of incorporation to increase the number of authorized shares of common stock from 100 million shares to 200 million shares, with shares voted as follows: 
  

 For

 
61,004,221

 Against

 
2,394,208

 Abstain

 
305,605

 There were no broker non-votes on the approval of the above amendment to our restated certificate of incorporation. 
 In addition, our stockholders ratified the appointment of CBIZ CPAs P.C. as our independent registered public accounting firm for the year ending December 31, 2026, with shares voted as follows: 
  

 For

 
62,953,351

 Against

 
172,420

 Abstain

 
578,263

 There were no broker non-votes on the ratification of our independent registered public accounting firm. 
 In addition, our stockholders approved, on an advisory basis, the compensation of our named executive officers disclosed in the Proxy Statement, with shares voted as follows: 
  

 For

 
37,628,483

 Against

 
914,331

 Abstain

 
62,591

 There were 25,098,629 broker non-votes on the approval, on an advisory basis, of the compensation of our named executive officers. 
  

 

 SIGNATURES 
 Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. 
  

 

 
REIN THERAPEUTICS, INC.

Dated: July 21, 2026
 

 

 
 /s/ Brian Windsor

 

 

 
Brian Windsor, Ph.D.,

 

 

 
President and Chief Executive Officer